The new infrastructure connects generative models, contract research organizations (CROs), and lab instrumentation into a cohesive, agentic loop. Rather than managing individual tasks, R&D teams configure specific goals, such as antibody screening or assay development. Agents then execute the necessary steps, handle data handoffs, and perform real-time analysis, ensuring that results are ready for review as soon as a scientist begins their workday.

For companies like Parabilis Medicines, this transition from standalone AI tools to integrated foundries represents a significant shift in operational capacity. By automating the intervals between experiments, lean teams can run multiple design strategies in parallel, comparing outcomes side by side rather than in sequence. Benchling, which supports over 1,300 organizations including Moderna and Sanofi, reports that these workflows are now available to all customers, with specialized configurations for therapeutic research, preclinical studies, and process development.